

Tutorial IV: Dynamic Predictions from Joint Models

Dimitris Rizopoulos

Department of Biostatistics, Erasmus University Medical Center

`d.rizopoulos@erasmusmc.nl`

Joint Modeling and Beyond

Meeting and Tutorials on Joint Modeling With Survival, Longitudinal, and Missing Data

April 15, 2016, Diepenbeek

Contents

1	Extensions of Joint Models	2
1.1	Parameterizations	3
1.2	Multiple Longitudinal Markers	21
1.3	Multiple Failure Times	24
1.4	Extensions & Parameterizations	28
2	Dynamic Predictions, Discrimination & Calibration	30
2.1	Survival Probabilities: Definitions	31
2.2	Survival Probabilities: Estimation	35

2.3	Dynamic Predictions using Landmarking	46
2.4	Longitudinal Responses: Definitions	50
2.5	Importance of the Parameterization	58
2.6	Model Discrimination	66
2.7	Calibration	72
2.8	Landmarking vs JM: An Example	76
2.9	Validation	81
2.10	Additional References	83
2.11	Medical Papers with Joint Modeling	91

Chapter 1

Extensions of Joint Models


1.1 Parameterizations

- The standard joint model

$$\left\{ \begin{array}{l} h_i(t \mid \mathcal{M}_i(t)) = h_0(t) \exp\{\gamma^\top w_i + \alpha m_i(t)\}, \\ \\ y_i(t) = m_i(t) + \varepsilon_i(t) \\ \\ y_i(t) = x_i^\top(t)\beta + z_i^\top(t)b_i + \varepsilon_i(t), \end{array} \right.$$

where $\mathcal{M}_i(t) = \{m_i(s), 0 \leq s < t\}$

1.1 Parameterizations (cont'd)



1.1 Parameterizations (cont'd)

- The standard joint model

$$\left\{ \begin{array}{l} h_i(t | \mathcal{M}_i(t)) = h_0(t) \exp\{\gamma^\top w_i + \alpha m_i(t)\}, \\ y_i(t) = m_i(t) + \varepsilon_i(t) \\ y_i(t) = x_i^\top(t)\beta + z_i^\top(t)b_i + \varepsilon_i(t), \end{array} \right.$$

where $\mathcal{M}_i(t) = \{m_i(s), 0 \leq s < t\}$

Is this the only option? Is this the most optimal choice?

1.1 Parameterizations (cont'd)

- Note: Inappropriate modeling of time-dependent covariates may result in surprising results
- Example: Cavender et al. (1992, J. Am. Coll. Cardiol.) conducted an analysis to test the effect of cigarette smoking on survival of patients who underwent coronary artery surgery
 - ▷ the estimated effect of current cigarette smoking was positive on survival although not significant (i.e., patients who smoked had higher probability of survival)
 - ▷ most of those who had died were smokers but many stopped smoking at the last follow-up before their death

1.1 Parameterizations (cont'd)

We need to carefully consider the functional form of time-dependent covariates

- Let's see some possibilities...

1.1 Parameterizations (cont'd)


- *Lagged Effects*: The hazard for an event at t is associated with the level of the marker at a previous time point:

$$h_i(t \mid \mathcal{M}_i(t)) = h_0(t) \exp\{\gamma^\top w_i + \alpha m_i(t_+^c)\},$$

where

$$t_+^c = \max(t - c, 0)$$

1.1 Parameterizations (cont'd)



1.1 Parameterizations (cont'd)


- *Time-dependent Slopes*: The hazard for an event at t is associated with both the current value and the slope of the trajectory at t (Ye et al., 2008, Biometrics):

$$h_i(t \mid \mathcal{M}_i(t)) = h_0(t) \exp\{\gamma^\top w_i + \alpha_1 m_i(t) + \alpha_2 m'_i(t)\},$$

where

$$m'_i(t) = \frac{d}{dt} \{x_i^\top(t)\beta + z_i^\top(t)b_i\}$$

1.1 Parameterizations (cont'd)




1.1 Parameterizations (cont'd)

- *Cumulative Effects*: The hazard for an event at t is associated with the whole area under the trajectory up to t :

$$h_i(t | \mathcal{M}_i(t)) = h_0(t) \exp\left\{ \gamma^\top w_i + \alpha \int_0^t m_i(s) ds \right\}$$

- Area under the longitudinal trajectory taken as a summary of $\mathcal{M}_i(t)$

1.1 Parameterizations (cont'd)



1.1 Parameterizations (cont'd)

- *Weighted Cumulative Effects (convolution)*: The hazard for an event at t is associated with the area under the weighted trajectory up to t :

$$h_i(t | \mathcal{M}_i(t)) = h_0(t) \exp\left\{ \gamma^\top w_i + \alpha \int_0^t \varpi(t-s) m_i(s) ds \right\},$$

where $\varpi(\cdot)$ an appropriately chosen weight function, e.g.,

- ▷ Gaussian density
- ▷ Student's- t density
- ▷ ...

1.1 Parameterizations (cont'd)

- *Random Effects*: The hazard for an event at t is associated only with the random effects of the longitudinal model:

$$h_i(t \mid \mathcal{M}_i(t)) = h_0(t) \exp(\gamma^\top w_i + \alpha^\top b_i)$$

- Features:
 - ▷ avoids numerical integration for the survival function
 - ▷ interpretation of α more difficult, especially in high-dimensional random-effects settings

1.1 Parameterizations (cont'd)

- Example: Sensitivity of inferences for the longitudinal process to the choice of the parameterization for the AIDS data
- We use the same mixed model as before, i.e.,

$$\begin{aligned}
 y_i(t) &= m_i(t) + \varepsilon_i(t) \\
 &= \beta_0 + \beta_1 t + \beta_2 \{t \times \text{ddI}_i\} + b_{i0} + b_{i1} t + \varepsilon_i(t)
 \end{aligned}$$

and the following four survival submodels

1.1 Parameterizations (cont'd)

- Model I (current value)

$$h_i(t) = h_0(t) \exp\{\gamma \text{ddI}_i + \alpha_1 m_i(t)\}$$

- Model II (current value + current slope)

$$h_i(t) = h_0(t) \exp\{\gamma \text{ddI}_i + \alpha_1 m_i(t) + \alpha_2 m'_i(t)\},$$

where

$$\triangleright m'_i(t) = \beta_1 + \beta_2 \text{ddI}_i + b_{i1}$$

1.1 Parameterizations (cont'd)

- Model III (random slope)

$$h_i(t) = h_0(t) \exp\{\gamma \text{ddI}_i + \alpha_3 b_{i1}\}$$


- Model IV (area)

$$h_i(t) = h_0(t) \exp\left\{\gamma \text{ddI}_i + \alpha_4 \int_0^t m_i(s) ds\right\},$$

where

$$\triangleright \int_0^t m_i(s) ds = \beta_0 t + \frac{\beta_1}{2} t^2 + \frac{\beta_2}{2} \{t^2 \times \text{ddI}_i\} + b_{i0} t + \frac{b_{i1}}{2} t^2$$

1.1 Parameterizations (cont'd)



1.1 Parameterizations (cont'd)

- There are noticeable differences between the parameterizations
 - ▷ especially in the slope parameters
- Therefore, a sensitivity analysis should not stop at the standard joint model parameterization but also consider alternative association structures

1.2 Multiple Longitudinal Markers

- So far we have concentrated on a single continuous marker
- But very often we may have several markers we wish to study, some of which could be categorical
- **Example:** In the PBC dataset we have used serum bilirubin as the most important marker, but during follow-up several other markers have been recorded
 - ▷ serum cholesterol (continuous)
 - ▷ edema (3 categories)
 - ▷ ascites (2 categories)
 - ▷ ...

1.2 Multiple Longitudinal Markers (cont'd)

We need to extend the basic joint model!

- To handle multiple longitudinal markers of different types we use Generalized Linear Mixed Models
 - ▷ We assume Y_{i1}, \dots, Y_{iJ} for each subject, each one having a distribution in the exponential family, with expected value

$$m_{ij}(t) = E(y_{ij}(t) | b_{ij}) = g_j^{-1}\{x_{ij}^\top(t)\beta_j + z_{ij}^\top(t)b_{ij}\},$$

with $g(\cdot)$ denoting a link function

1.2 Multiple Longitudinal Markers (cont'd)

- ▷ Correlation between the outcomes is built by assuming a multivariate normal distribution for the random effects

$$b_i = (b_{i1}^\top, \dots, b_{iJ}^\top)^\top \sim \mathcal{N}(0, D)$$

- The expected value of each longitudinal marker is incorporated in the linear predictor of the survival submodel

$$h_i(t) = h_0(t) \exp\left\{ \gamma^\top w_i + \sum_{j=1}^J \alpha_j m_{ij}(t) \right\}$$

1.3 Multiple Failure Times

- Often multiple failure times are recorded
 - ▷ competing risks
 - ▷ recurrent events
- Example: In the PBC dataset \Rightarrow competing risks
 - ▷ Some patients received a liver transplantation
 - ▷ So far we have used the composite event, i.e. death or transplantation whatever comes first
 - ▷ When interest only is on one type of event, the other should be considered as a competing risk

1.3 Multiple Failure Times (cont'd)

- Joint models with competing risks:

$$\left\{ \begin{array}{l} y_i(t) = m_i(t) + \varepsilon_i(t) = x_i^\top(t)\beta + z_i^\top(t)b_i + \varepsilon_i(t), \\ h_i^d(t) = h_0^d(t) \exp\{\gamma_d^\top w_i + \alpha_d m_i(t)\}, \\ h_i^{tr}(t) = h_0^{tr}(t) \exp\{\gamma_{tr}^\top w_i + \alpha_{tr} m_i(t)\}, \end{array} \right.$$

where

- ▷ $h_i^d(t)$ hazard function for death
- ▷ $h_i^{tr}(t)$ hazard function for transplantation

1.3 Multiple Failure Times (cont'd)

- Multiple Failure Times: recurrent events
- **Example:** In the PBC dataset \Rightarrow recurrent events
 - ▷ Patients showed irregular visiting patterns
 - ▷ So far, when we fitted the joint model we assumed that the visiting process is non-informative
 - ▷ If this assumption is violated, we should also model this process in order to obtain valid inferences

1.3 Multiple Failure Times (cont'd)

- Joint model with recurrent (visiting process) & terminal events

$$\left\{ \begin{array}{l} y_i(t) = m_i(t) + \varepsilon_i(t) = x_i^\top(t)\beta + z_i^\top(t)b_i + \varepsilon_i(t), \\ r_i(t) = r_0(t) \exp\{\gamma_r^\top w_{ri} + \alpha_r m_i(t) + \mathbf{v}_i\}, \\ h_i(t) = h_0(t) \exp\{\gamma_h^\top w_{hi} + \alpha_h m_i(t) + \zeta \mathbf{v}_i\}, \end{array} \right.$$

with

- ▷ $r_i(t)$ hazard function for the recurrent events
- ▷ $h_i(t)$ hazard function for the terminal event
- ▷ \mathbf{v}_i frailty term accounting for the correlation in the recurrent events

1.4 Extensions & Parameterizations

- Features of multivariate joint models
 - ▷ using CI is straightforward to extend joint models to multiple longitudinal outcomes of different types, and multiple failure times
 - ▷ computationally much more intensive due to requirement for high dimensional numerical integrations with respect to the random effects

1.4 Extensions & Parameterizations (cont'd)

- Note: In the previous extensions of joint models, i.e.,
 - ▷ multiple longitudinal markers
 - ▷ multiple failure times

we used the default parameterization that includes the current value term $m_i(t)$ in the linear predictor of the survival submodel(s)

Nonetheless, all the other parameterizations we have seen earlier are also applicable

Chapter 2

Dynamic Predictions, Discrimination & Calibration

2.1 Survival Probabilities: Definitions


- Nowadays there is great interest for prognostic models and their application to personalized medicine
- Examples are numerous
 - ▷ cancer research, cardiovascular diseases, HIV research, . . .

Physicians are interested in accurate prognostic tools that will inform them about the future prospect of a patient in order to adjust medical care

2.1 Survival Probabilities: Definitions (cont'd)

- We are interested in predicting survival probabilities for a new patient j that has provided a set of serum bilirubin measurements up to a specific time point t
- **Example:** We consider Patients 2 and 25 from the PBC dataset that have provided us with 9 and 12 serum bilirubin measurements, respectively
 - ▷ **Dynamic Prediction** survival probabilities are dynamically updated as additional longitudinal information is recorded
- We need to account for the endogenous nature of the marker
 - ▷ providing measurements up to time point $t \Rightarrow$ the patient was still alive at time t

2.1 Survival Probabilities: Definitions (cont'd)



2.1 Survival Probabilities: Definitions (cont'd)

- More formally, for a new subject j we have available measurements up to time point t

$$\mathcal{Y}_j(t) = \{y_j(s), 0 \leq s \leq t\}$$

and we are interested in

$$\pi_j(u | t) = \Pr\{T_j^* \geq u \mid T_j^* > t, \mathcal{Y}_j(t), \mathcal{D}_n\},$$

where

- ▷ where $u > t$, and
- ▷ \mathcal{D}_n denotes the sample on which the joint model was fitted

2.2 Survival Probabilities: Estimation

- We assume that the joint model has been fitted to the data at hand
- Based on the fitted model we can estimate the conditional survival probabilities
(Rizopoulos, 2011, Biometrics)

2.2 Survival Probabilities: Estimation (cont'd)

- $\pi_j(u | t)$ can be rewritten as

$$\pi_j(u | t) = \int \frac{S_j\{u | \mathcal{M}_j(u, b_j, \theta); \theta\}}{S_j\{t | \mathcal{M}_j(t, b_j, \theta); \theta\}} p(b_j | T_j^* > t, \mathcal{Y}_j(t); \theta) db_j$$

- A naive estimator for $\pi_j(u | t)$ can be constructed by plugging-in the MLEs and the Empirical Bayes estimates

$$\tilde{\pi}_j(u | t) = \frac{S_j\{u | \mathcal{M}_j(u, \hat{b}_j, \hat{\theta}); \hat{\theta}\}}{S_j\{t | \mathcal{M}_j(t, \hat{b}_j, \hat{\theta}); \hat{\theta}\}}$$

- ▷ this works relatively well in practice, but
- ▷ standard errors are difficult to compute

2.2 Survival Probabilities: Estimation (cont'd)

- It is convenient to proceed using a Bayesian formulation of the problem \Rightarrow
 $\pi_j(u | t)$ can be written as

$$\Pr\{T_j^* \geq u | T_j^* > t, \mathcal{Y}_j(t), \mathcal{D}_n\} = \int \Pr\{T_j^* \geq u | T_j^* > t, \mathcal{Y}_j(t); \theta\} p(\theta | \mathcal{D}_n) d\theta$$

- We have already seen the first part of the integrand

$$\begin{aligned} \Pr\{T_j^* \geq u | T_j^* > t, \mathcal{Y}_j(t); \theta\} &= \\ &= \int \frac{S_j\{u | \mathcal{M}_j(u, b_j, \theta); \theta\}}{S_j\{t | \mathcal{M}_j(t, b_j, \theta); \theta\}} p(b_j | T_j^* > t, \mathcal{Y}_j(t); \theta) db_j \end{aligned}$$

2.2 Survival Probabilities: Estimation (cont'd)

- Provided that the sample size is sufficiently large, we can approximate the posterior of the parameters by

$$\{\theta \mid \mathcal{D}_n\} \sim \mathcal{N}(\hat{\theta}, \hat{\mathcal{H}}),$$

where

- ▷ $\hat{\theta}$ are the MLEs, and
- ▷ $\hat{\mathcal{H}}$ their asymptotic covariance matrix

2.2 Survival Probabilities: Estimation (cont'd)

- A Monte Carlo estimate of $\pi_j(u | t)$ can be obtained using the following simulation scheme:

Step 1. draw $\theta^{(\ell)} \sim \mathcal{N}(\hat{\theta}, \hat{\mathcal{H}})$

Step 2. draw $b_j^{(\ell)} \sim \{b_j | T_j^* > t, \mathcal{Y}_j(t), \theta^{(\ell)}\}$

Step 3. compute $\pi_j^{(\ell)}(u | t) = S_j\{u | \mathcal{M}_j(u, b_j^{(\ell)}, \theta^{(\ell)}); \theta^{(\ell)}\} / S_j\{t | \mathcal{M}_j(t, b_j^{(\ell)}, \theta^{(\ell)}); \theta^{(\ell)}\}$

- Repeat Steps 1–3, $\ell = 1, \dots, L$ times, where L denotes the number of Monte Carlo samples

2.2 Survival Probabilities: Estimation (cont'd)

- Steps 1 and 3 are straightforward
- In Step 2 we need to sample from $\{b_j \mid T_j^* > t, \mathcal{Y}_j(t), \theta^{(\ell)}\}$, which is nonstandard
 - ▷ as n_i increases, this posterior converges to a multivariate normal distribution (Rizopoulos et al., Biometrika, 2008)
 - ▷ we use a Metropolis-Hastings algorithm with multivariate t proposals

2.2 Survival Probabilities: Estimation (cont'd)

- **Example:** Dynamic predictions of survival probabilities for Patients 2 & 25 from the PBC dataset: We fit the joint model
- Longitudinal submodel
 - ▷ fixed effects: Linear & quadratic time, treatment and their interaction
 - ▷ random effects: Intercept, linear & quadratic time effects
- Survival submodel
 - ▷ treatment effect + *underlying* serum bilirubin level
 - ▷ piecewise-constant baseline hazard in 7 intervals


2.2 Survival Probabilities: Estimation (cont'd)

- Based on the fitted joint model we estimate $\pi_j(u | t)$ for Patients 2 and 25
- We use 500 Monte Carlo samples, and we took as estimate


$$\hat{\pi}_j(u | t) = \text{median}\{\pi_j^{(\ell)}(u | t), \ell = 1, \dots, L\}$$

and calculated a corresponding 95% pointwise CIs



2.2 Survival Probabilities: Estimation (cont'd)





2.2 Survival Probabilities: Estimation (cont'd)




2.2 Survival Probabilities: Estimation (cont'd)





2.2 Survival Probabilities: Estimation (cont'd)





2.2 Survival Probabilities: Estimation (cont'd)



2.2 Survival Probabilities: Estimation (cont'd)



2.2 Survival Probabilities: Estimation (cont'd)



2.2 Survival Probabilities: Estimation (cont'd)

R> Individualized predictions of survival probabilities are computed by function `survfitJM()` – for example, for Patient 2 from the PBC dataset we have

```
sfit <- survfitJM(jointFit, newdata = pbc2[pbc2$id == "2", ])
```

```
sfit
```

```
plot(sfit)
```

```
plot(sfit, include.y = TRUE)
```

2.3 Dynamic Predictions using Landmarking

- Dynamic predictions of survival probabilities can be also derived using a landmark approach
- How this works?
 - ▷ choose a landmark point t , e.g., for the future patient of interest the last time point she was alive
 - ▷ from the original dataset keep only the patients who were at risk at the landmark
 - ▷ fit a Cox model to this dataset including the last available value of the biomarker as baseline covariate

$$h_i(u - t) = h_0(u - t) \exp\{\gamma^\top w_i + \alpha \tilde{y}_i(t)\}, \quad u > t$$

2.3 Dyn. Predictions using Landmarking (cont'd)

- ▷ for the new patient compute her survival probability at u using the fitted Cox model and the Breslow estimator

$$\hat{\pi}_j^{LM}(u | t) = \exp \left[-\hat{H}_0(u) \exp \{ \hat{\gamma}^\top w_j + \hat{\alpha} \tilde{y}_j(t) \} \right],$$

where


$$\hat{H}_0(u) = \sum_{i \in \mathcal{R}(t)} \frac{I(T_i \leq u) \delta_i}{\sum_{\ell \in \mathcal{R}(u)} \exp \{ \hat{\gamma}^\top w_\ell + \hat{\alpha} \tilde{y}_\ell(t) \}},$$

and $\mathcal{R}(t) = \{i : T_i > t\}$

2.3 Dyn. Predictions using Landmarking (cont'd)

- Sometimes landmarking works, **but not always!**
- Main differences between landmarking and joint modeling
 - ▷ **Extrapolation:**
 - * both require the level of the marker at t
 - * landmarking extrapolates the last biomarker value (Last Value Carried Forward approach)
 - * joint modeling builds the subject-specific profile which extrapolates up to t
 - * from a biological point of view the joint modeling approach seems more logical than landmarking

2.3 Dyn. Predictions using Landmarking (cont'd)



2.3 Dyn. Predictions using Landmarking (cont'd)

- Main differences between landmarking and joint modeling

▷ **Implicit processes:**

Landmarking	Joint Modeling
* MCAR missing data long. process	* MAR missing data long. process
* non-informative visiting process	* visiting process allowed to depend on long. history
* non-informative censoring	* censoring allowed to depend on long. history

2.4 Longitudinal Responses: Definitions

- In some occasions it may be also of interest to predict the longitudinal outcome
- We can proceed in the same manner as for the survival probabilities: We have available measurements up to time point t

$$\mathcal{Y}_j(t) = \{y_j(s), 0 \leq s \leq t\}$$

and we are interested in

$$\omega_j(u | t) = E\{y_j(u) | T_j^* > t, \mathcal{Y}_j(t), \mathcal{D}_n\}, \quad u > t$$

2.4 Longitudinal Responses: Definitions (cont'd)

- To estimate $\omega_j(u | t)$ we can follow a similar approach as for $\pi_j(u | t)$ – Namely, $\omega_j(u | t)$ is written as:

$$E\{y_j(u) | T_j^* > t, \mathcal{Y}_j(t), \mathcal{D}_n\} = \int E\{y_j(u) | T_j^* > t, \mathcal{Y}_j(t), \mathcal{D}_n; \theta\} p(\theta | \mathcal{D}_n) d\theta$$

- With the first part of the integrand given by:

$$\begin{aligned} E\{y_j(u) | T_j^* > t, \mathcal{Y}_j(t), \mathcal{D}_n; \theta\} &= \\ &= \int \{x_j^\top(u)\beta + z_j^\top(u)b_j\} p(b_j | T_j^* > t, \mathcal{Y}_j(t); \theta) db_j \end{aligned}$$

2.4 Longitudinal Responses: Estimation (cont'd)

- A similar Monte Carlo simulation scheme:

Step 1. draw $\theta^{(\ell)} \sim \mathcal{N}(\hat{\theta}, \hat{\mathcal{H}})$

Step 2. draw $b_j^{(\ell)} \sim \{b_j \mid T_j^* > t, \mathcal{Y}_j(t), \theta^{(\ell)}\}$

Step 3. compute $\omega_j^{(\ell)}(u \mid t) = x_j^\top(u)\beta^{(\ell)} + z_j^\top(u)b_j^{(\ell)}$

- **Note:** Prediction intervals can be easily computed by replacing Step 3 with a draw from:

$$\omega_j^{(\ell)}(u \mid t) \sim \mathcal{N}\left\{x_j^\top(u)\beta^{(\ell)} + z_j^\top(u)b_j^{(\ell)}, \quad [\sigma^2]^{(\ell)}\right\}$$

2.4 Longitudinal Responses: Estimation (cont'd)

- **Example:** Dynamic predictions of serum bilirubin for Patients 2 & 25 from the PBC dataset: We fit the joint model
- Longitudinal submodel
 - ▷ fixed effects: Linear & quadratic time, treatment and their interaction
 - ▷ random effects: Intercept, linear & quadratic time effects
- Survival submodel
 - ▷ treatment effect + *underlying* serum bilirubin level
 - ▷ piecewise-constant baseline hazard in 7 intervals

2.4 Longitudinal Responses: Estimation (cont'd)


- Based on the fitted joint model we estimate $\omega_j(u | t)$ for Patients 2 and 25
- Point estimates

$$\hat{\omega}_j(u | t) = x_j^\top(u) \hat{\beta} + z_j^\top(u) \hat{b}_j,$$


where $\hat{\beta}$: MLEs & \hat{b}_j : empirical Bayes estimates

- 95% pointwise CIs
 - ▷ simulation scheme: 2.5% and 97.5% percentiles of 500 Monte Carlo samples of $\omega_j^{(\ell)}(u | t)$


2.4 Longitudinal Responses: Estimation (cont'd)




2.4 Longitudinal Responses: Estimation (cont'd)




2.4 Longitudinal Responses: Estimation (cont'd)




2.4 Longitudinal Responses: Estimation (cont'd)



2.4 Longitudinal Responses: Estimation (cont'd)



2.4 Longitudinal Responses: Estimation (cont'd)



2.4 Longitudinal Responses: Estimation (cont'd)

R> Individualized predictions for the longitudinal outcome are computed by function `predict()` – for example, for Patient 2 from the PBC dataset we have function

```
lfit <- predict(jointFit, newdata = pbc2[pbc2$id == "2", ],
               type = "Subject", interval = "conf", returnData = TRUE)
```

```
lfit
```

```
xyplot(pred + low + upp ~ year, data = lfit, type = "l",
        lty = c(1,2,2), col = c(2,1,1), lwd = 2)
```

2.4 Longitudinal Responses: Estimation (cont'd)

R> Web interface using the **shiny** package

```
library(shiny)
```

```
runApp(file.path(.Library, "JMbayes/demo"))
```

2.5 Importance of the Parameterization

- All previous predictions were based on the standard joint model


$$\left\{ \begin{array}{l} h_i(t | \mathcal{M}_i(t)) = h_0(t) \exp\{\gamma^\top w_i + \alpha m_i(t)\}, \\ y_i(t) = m_i(t) + \varepsilon_i(t) \\ y_i(t) = x_i^\top(t)\beta + z_i^\top(t)b_i + \varepsilon_i(t), \end{array} \right.$$

where $\mathcal{M}_i(t) = \{m_i(s), 0 \leq s < t\}$

2.5 Importance of the Parameterization (cont'd)

- We have seen earlier that there are several alternative parameterizations (see Section 5.1)
- Relevant questions:
 - ▷ Does the assumed parameterization affect predictions?
 - ▷ Which parameterization is the most optimal?
- Example: We compare predictions for the longitudinal and survival outcomes under different parameterizations for Patient 51 from the PBC study

2.5 Importance of the Parameterization (cont'd)



2.5 Importance of the Parameterization (cont'd)

- Predictions based on five joint models for the PBC dataset
 - ▷ the same longitudinal submodel as before, and
 - ▷ relative risk submodels:

$$h_i(t) = h_0(t) \exp\{\gamma D\text{-pnc}_i + \alpha_1 m_i(t)\},$$

$$h_i(t) = h_0(t) \exp\{\gamma D\text{-pnc}_i + \alpha_2 m'_i(t)\},$$

$$h_i(t) = h_0(t) \exp\{\gamma D\text{-pnc}_i + \alpha_1 m_i(t) + \alpha_2 m'_i(t)\},$$


2.5 Importance of the Parameterization (cont'd)

$$h_i(t) = h_0(t) \exp \left\{ \gamma \text{D-pnc}_i + \alpha_3 \int_0^t m_i(s) ds \right\},$$


$$h_i(t) = h_0(t) \exp \left\{ \gamma \text{D-pnc}_i + \alpha_4 \int_0^t \phi(t-s) m_i(s) ds \right\},$$

where $\phi(\cdot)$ standard normal pdf

2.5 Importance of the Parameterization (cont'd)



2.5 Importance of the Parameterization (cont'd)



2.5 Importance of the Parameterization (cont'd)

- The chosen parameterization can influence the derived predictions
 - ▷ especially for the survival outcome
- My current work: How to optimally choose parameterization?
 - ▷ per subject (personalized medicine)
- Quite promising results from the Bayesian approach using Bayesian Model Averaging techniques
 - ▷ it can be done with package **JMbayes**,
 - ▷ it falls a bit outside the scope of this course, but
 - ▷ I can provide information if interested...

2.6 Model Discrimination

- Often clinical interest lies in the predictive performance of a marker
 - ▷ this could be useful in medical practice if the marker alone offers good enough discrimination
- Hence, often we are also interested in the discriminative capability of the *whole* model incorporating the baseline covariates as well
 - ▷ especially when no single prognostic factor can accurately enough discriminate between patients

2.6 Model Discrimination (cont'd)

- We assume the following setting
 - ▷ using the available longitudinal data up to time t , $\mathcal{Y}_j(t) = \{y_j(s), 0 \leq s \leq t\}$
 - ▷ we are interested in events in the medically relevant interval $(t, t + \Delta t]$

- Based on the fitted joint model and for a particular threshold value $c \in [0, 1]$, we can term a subject as a **case** if

$$\pi_j(t + \Delta t \mid t) \leq c$$

2.6 Model Discrimination (cont'd)

- Following, we can define sensitivity

$$\Pr\{\pi_j(t + \Delta t | t) \leq c \mid T_j^* \in (t, t + \Delta t]\},$$

specificity

$$\Pr\{\pi_j(t + \Delta t | t) > c \mid T_j^* > t + \Delta t\},$$

and the corresponding AUC

$$\begin{aligned} & \text{AUC}(t, \Delta t) \\ &= \Pr[\pi_i(t + \Delta t | t) < \pi_j(t + \Delta t | t) \mid \{T_i^* \in (t, t + \Delta t]\} \cap \{T_j^* > t + \Delta t\}] \end{aligned}$$

2.6 Model Discrimination (cont'd)

- Estimation of $AUC(t, \Delta t)$ can be based on similar arguments as Harrell's C index

$$\widehat{AUC}(t, \Delta t) = \widehat{AUC}_1(t, \Delta t) + \widehat{AUC}_2(t, \Delta t)$$

where

$$\widehat{AUC}_1(t, \Delta t) = \frac{\sum_{i=1}^n \sum_{j=1; j \neq i}^n I\{\hat{\pi}_i(t + \Delta t | t) < \hat{\pi}_j(t + \Delta t | t)\} \times I\{\Omega_{ij}^{(1)}(t)\}}{\sum_{i=1}^n \sum_{j=1; j \neq i}^n I\{\Omega_{ij}^{(1)}(t)\}},$$

with

$$\Omega_{ij}^{(1)}(t) = [\{T_i \in (t, t + \Delta t]\} \cap \{\delta_i = 1\}] \cap \{T_j > t + \Delta t\}$$

2.6 Model Discrimination (cont'd)

- And

$$\widehat{\text{AUC}}_2(t, \Delta t) = \frac{\sum_{i=1}^n \sum_{j=1; j \neq i}^n I\{\hat{\pi}_i(t + \Delta t | t) < \hat{\pi}_j(t + \Delta t | t)\} \times I\{\Omega_{ij}^{(2)}(t)\} \times \widehat{K}}{\sum_{i=1}^n \sum_{j=1; j \neq i}^n I\{\Omega_{ij}^{(2)}(t)\} \times \widehat{K}},$$

with

$$\Omega_{ij}^{(2)}(t) = [\{T_i \in (t, t + \Delta t]\} \cap \{\delta_i = 0\}] \cap \{T_j > t + \Delta t\}$$

and

$$\widehat{K} = 1 - \hat{\pi}_i(t + \Delta t | T_i)$$

2.6 Model Discrimination (cont'd)

R> For a fitted joint model $\hat{AUC}(t, \Delta t)$ is calculated by function `aucJM()` – for the PBC dataset

```
# AUC(t = 7, Delta t = 2)
aucJM(jointFit, newdata = pbc2, Tstart = 7, Dt = 2)
```

2.7 Calibration

- We have covered *discrimination*, i.e.,
 - ▷ how well can the longitudinal biomarker(s) discriminate between subject of low and high risk for the event
- Another relevant measure for quantifying predictive ability is *calibration*, i.e.,
 - ▷ how well can the longitudinal biomarker(s) accurately predict future events
- In standard survival analysis and on the latter front there has been a lot of work on extensions of the Brier score (see Gerds and Schumacher, (2006) and references therein)

2.7 Calibration (cont'd)

- In the joint modeling framework we need to take into account the dynamic nature of the longitudinal marker
- The expected error of prediction has the form

$$\text{PE}(u | t) = E[L\{N_i(u) - \pi_i(u | t)\}]$$

where

- ▷ $N_i(t) = I(T_i^* > t)$ is the event status at time t
- ▷ $L(\cdot)$ denotes a loss function, such as the absolute or square loss

2.7 Calibration (cont'd)

- An estimator for $PE(u | t)$ that accounts for censoring has been proposed by Henderson et al. (2002)

$$\widehat{PE}(u | t) = \{\mathcal{R}(t)\}^{-1} \sum_{i:T_i \geq t} I(T_i > u)L\{1 - \hat{\pi}_i(u | t)\} + \delta_i I(T_i < u)L\{0 - \hat{\pi}_i(u | t)\} \\ + (1 - \delta_i)I(T_i < u) \left[\hat{\pi}_i(u | T_i)L\{1 - \hat{\pi}_i(u | t)\} + \{1 - \hat{\pi}_i(u | T_i)\}L\{0 - \hat{\pi}_i(u | t)\} \right]$$

where

- ▷ $\mathcal{R}(t)$ denotes the number of subjects at risk at t
- ▷ **red part**: subjects still alive at u
- ▷ **blue part**: subjects who died before u
- ▷ **green part**: subject censored before u

2.7 Calibration (cont'd)

R> For a fitted joint model $\widehat{PE}(u | t)$ is calculated by function `prederrJM()` – for the PBC dataset

```
# PE(u = 9 | t = 7)
prederrJM(jointFit, newdata = pbc2, Tstart = 7, Thoriz = 9)
```


2.8 Landmarking vs JM: An Example

- We have earlier seen that the landmark approach also provides estimates of dynamic survival probabilities $\pi_j(u | t)$
 - ▷ we make here a comparison here with joint modeling for the PBC dataset

- Joint models:

- ▷ Longitudinal process:

$$\begin{aligned}
 y_i(t) = & \beta_1 \text{Plcb}_i + \beta_2 \text{D-penc}_i + \beta_3 \{B_1(t, \lambda) \times \text{Plcb}_i\} + \beta_4 \{B_1(t, \lambda) \times \text{D-penc}_i\} \\
 & + \beta_5 \{B_2(t, \lambda) \times \text{Plcb}_i\} + \beta_6 \{B_2(t, \lambda) \times \text{D-penc}_i\} \\
 & + \beta_7 \{B_3(t, \lambda) \times \text{Plcb}_i\} + \beta_8 \{B_3(t, \lambda) \times \text{D-penc}_i\} \\
 & + b_{i0} + b_{i1} B_1(t, \lambda) + b_{i2} B_2(t, \lambda) + b_{i3} B_3(t, \lambda) + \varepsilon_i(t),
 \end{aligned}$$

2.8 Landmarking vs JM: An Example (cont'd)

- Joint models:

- ▷ Survival process:

$$M_1 : h_i(t) = h_0(t) \exp\{\gamma_1 \text{D-penc}_i + \gamma_2 \text{Age}_i + \gamma_3 \text{Female}_i + \alpha_1 m_i(t)\},$$

$$M_2 : h_i(t) = h_0(t) \exp\{\gamma_1 \text{D-penc}_i + \gamma_2 \text{Age}_i + \gamma_3 \text{Female}_i + \alpha_1 m_i(t) + \alpha_2 m'_i(t)\},$$

$$M_3 : h_i(t) = h_0(t) \exp\left\{\gamma_1 \text{D-penc}_i + \gamma_2 \text{Age}_i + \gamma_3 \text{Female}_i + \alpha_1 \int_0^t m_i(s) ds\right\},$$

$$M_4 : h_i(t) = h_0(t) \exp(\gamma_1 \text{D-penc}_i + \gamma_2 \text{Age}_i + \gamma_3 \text{Female}_i + \alpha_1 b_{i0} + \alpha_2 b_{i1} + \alpha_3 b_{i2} + \alpha_4 b_{i3}),$$

2.8 Landmarking vs JM: An Example (cont'd)

- We focus on the interval $[t = 7, u = 9]$ and we fit a series of Cox models to the patients at risk at $t = 7$ with corresponding association structures to the previous joint models, i.e.,

$$M_5 : h_i(u - 7) = h_0(u - 7) \exp\{\gamma_1 \mathbf{D-penc}_i + \gamma_2 \mathbf{Age}_i + \gamma_3 \mathbf{Female}_i + \alpha_1 \tilde{y}_i(7)\},$$

$$M_6 : h_i(u - 7) = h_0(u - 7) \exp\{\gamma_1 \mathbf{D-penc}_i + \gamma_2 \mathbf{Age}_i + \gamma_3 \mathbf{Female}_i + \alpha_1 \tilde{y}_i(7) + \alpha_2 \tilde{y}'_i(7)\},$$

$$M_7 : h_i(u - 7) = h_0(u - 7) \exp\left\{\gamma_1 \mathbf{D-penc}_i + \gamma_2 \mathbf{Age}_i + \gamma_3 \mathbf{Female}_i + \alpha_1 \sum_{s=0}^7 y_i(s) \Delta s\right\},$$

2.8 Landmarking vs JM: An Example (cont'd)

where

- ▷ $\tilde{y}'_i(7)$ denotes the slope defined from the last two available measurements of each patient
 - ▷ $\sum_{s=0}^7 y_i(s) \Delta s$ denotes the area under the step function defined from the observed square root aortic gradient measurements up to 7 years
- We evaluate both discrimination and calibration
 - ▷ calibration: $\widehat{PE}(9|7)$ and $\widehat{IPE}(9|7)$ using the absolute loss function
 - ▷ discrimination: $\widehat{AUC}(9|7)$ and $\widehat{C}_{dyn}^{\Delta t=2}$ based on the interval $[0, 10]$ years

2.8 Landmarking vs JM: An Example (cont'd)

	$\widehat{PE}(9 7)$	$\widehat{IPE}(9 7)$	$\widehat{AUC}(9 7)$	$\widehat{C}_{dyn}^{\Delta t=2}$
M_1 : JM value	0.201	0.118	0.787	0.854
M_2 : JM value+slope	0.197	0.114	0.793	0.855
M_3 : JM area	0.191	0.112	0.758	0.839
M_4 : JM shared RE	0.191	0.108	0.807	0.840
M_5 : Cox _{LM} value	0.229	0.127	0.702	0.841
M_6 : Cox _{LM} value+slope	0.227	0.126	0.710	0.825
M_7 : Cox _{LM} area	0.226	0.125	0.697	0.827

- For this particular dataset and comparing the same parameterization we observe that joint modeling is better in terms of both calibration and discrimination

2.9 Validation

- Validation of both discrimination and calibration measures can be achieved with standard re-sampling techniques
 - ▷ cross-validation (leave-one-out or better 10-fold)
 - ▷ Bootstrap

- In general time consuming because it requires fitting the joint model many times
 - ▷ take advantage of parallel computing (e.g., using package **parallel**)

The End of Tutorial IV!

2.10 Additional References

- Andrinopoulou, E.R., Rizopoulos, D., Takkenberg, J. and Lesaffre, E. (2014). Joint modeling of two longitudinal outcomes and competing risk data. *Statistics in Medicine*, to appear.
- Brown, E. and Ibrahim, J. (2003). A Bayesian semiparametric joint hierarchical model for longitudinal and survival data. *Biometrics* **59**, 221–228.
- Brown, E. Ibrahim, J. and DeGruttola, V. (2005). A flexible B-spline model for multiple longitudinal biomarkers and survival. *Biometrics* **61**, 64–73.
- Chi, Y.-Y. and Ibrahim, J. (2006). Joint models for multivariate longitudinal and multivariate survival data. *Biometrics* **62**, 432–445.
- DeGruttola, V. and Tu, X. (1994). Modeling progression of CD-4 lymphocyte count and its relationship to survival time. *Biometrics* **50**, 1003–1014.
- Elashoff, R., Li, G. and Li, N. (2008). A joint model for longitudinal measurements and survival data in the presence of multiple failure types. *Biometrics* **64**, 762–771.

2.10 Additional References (cont'd)

- Faucett, C. and Thomas, D. (1996). Simultaneously modelling censored survival data and repeatedly measured covariates: A Gibbs sampling approach. *Statistics in Medicine* **15**, 1663–1685.
- Gerds, T. and Schumacher, M. (2006). Consistent estimation of the expected Brier score in general survival models with right-censored event times. *Biometrical Journal* **48**, 1029–1040.
- Heagerty, P. and Zheng, Y. (2005). Survival model predictive accuracy and ROC curves. *Biometrics* **61**, 92–105.
- Henderson, R., Diggle, P. and Dobson, A. (2000). Joint modelling of longitudinal measurements and event time data. *Biostatistics* **1**, 465–480.
- Henderson, R., Diggle, P. and Dobson, A. (2002). Identification and efficacy of longitudinal markers for survival. *Biostatistics* **3**, 33–50.
- Hsieh, F., Tseng, Y.-K. and Wang, J.-L. (2006). Joint modeling of survival and longitudinal data: Likelihood approach revisited. *Biometrics* **62**, 1037–1043.

2.10 Additional References (cont'd)

- Lin, H., Turnbull, B., McCulloch, C. and Slate, E. (2002). Latent class models for joint analysis of longitudinal biomarker and event process: Application to longitudinal prostate-specific antigen readings and prostate cancer. *Journal of the American Statistical Association* **97**, 53–65.
- Liu, L. and Huang, X. (2009). Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to a study on acquired immune deficiency syndrome. *Journal of the Royal Statistical Society, Series C* **58**, 65–81.
- Proust-Lima, C., Joly, P., Dartigues, J. and Jacqmin-Gadda, H. (2009). Joint modelling of multivariate longitudinal outcomes and a time-to-event: A nonlinear latent class approach. *Computational Statistics and Data Analysis* **53**, 1142–1154.
- Proust-Lima, C. and Taylor, J. (2009). Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: A joint modeling approach. *Biostatistics* **10**, 535–549.
- Rizopoulos, D. (2012). Fast fitting of joint models for longitudinal and event time data using a pseudo-adaptive Gaussian quadrature rule. *Computational Statistics and Data Analysis* **56**, 491–501.
- Rizopoulos, D. (2011). Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data. *Biometrics* **67**, 819–829.

2.10 Additional References (cont'd)

- Rizopoulos, D. (2010). JM: An R package for the joint modelling of longitudinal and time-to-event data. *Journal of Statistical Software* **35** (9), 1–33.
- Rizopoulos, D. and Ghosh, P. (2011). A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time-to-event. *Statistics in Medicine* **30**, 1366–1380.
- Rizopoulos, D., Hatfield, L.A., Carlin, B.P. and Takkenberg, J.J.M. (2014). Combining dynamic predictions from joint models for longitudinal and time-to-event data using Bayesian model averaging. *Journal of the American Statistical Association* **109**, 1385–1397.
- Rizopoulos, D., Murawska, M., Andrinopoulou, E.-R., Molenberghs, G., Takkenberg, J. and Lesaffre, E. (2013). Dynamic predictions with time-dependent covariates in survival analysis using joint modeling and landmarking. *Submitted*.
- Rizopoulos, D. and Lesaffre, E. (2014). Introduction to the special issue on joint modelling techniques. *Statistical Methods in Medical Research* **23**, 3–10.
- Rizopoulos, D., Verbeke, G. and Lesaffre, E. (2009). Fully exponential Laplace approximation for the joint modelling of survival and longitudinal data. *Journal of the Royal Statistical Society, Series B* **71**, 637–654.

2.10 Additional References (cont'd)

- Rizopoulos, D., Verbeke, G., Lesaffre, E. and Vanrenterghem, Y. (2008). A two-part joint model for the analysis of survival and longitudinal binary data with excess zeros. *Biometrics* **64**, 611–619.
- Rizopoulos, D., Verbeke, G. and Molenberghs, G. (2010). Multiple-imputation-based residuals and diagnostic plots for joint models of longitudinal and survival outcomes. *Biometrics* **66**, 20–29.
- Rizopoulos, D., Verbeke, G. and Molenberghs, G. (2008). Shared parameter models under random effects misspecification. *Biometrika* **95**, 63–74.
- Rubin, D. (1976). Inference and missing data. *Biometrika* **63**, 581–592.
- Song, X., Davidian, M. and Tsiatis, A. (2002). A semiparametric likelihood approach to joint modeling of longitudinal and time-to-event data. *Biometrics* **58**, 742–753.
- Taylor, J., Park, Y., Ankerst, D., Proust-Lima, C., Williams, S., Kestin, L., Bae, K., Pickles, T., and Sandler, H. (2013). Real-time individual predictions of prostate cancer recurrence using joint models. *Biometrics*, **69**, 206–213.
- Tseng, Y.-K., Hsieh, F. and Wang, J.-L. (2005). Joint modelling of accelerated failure time and longitudinal data. *Biometrika* **92**, 587–603.

2.10 Additional References (cont'd)

- Tsiatis, A. and Davidian, M. (2001). A semiparametric estimator for the proportional hazards model with longitudinal covariates measured with error. *Biometrika* **88**, 447–458.
- Tsiatis, A. and Davidian, M. (2004). Joint modeling of longitudinal and time-to-event data: An overview. *Statistica Sinica* **14**, 809–834.
- Tsiatis, A., DeGruttola, V., and Wulfsohn, M. (1995). Modeling the relationship of survival to longitudinal data measured with error: Applications to survival and CD4 counts in patients with AIDS. *Journal of the American Statistical Association* **90**, 27–37.
- Viviani, S., Alfó, M. and Rizopoulos, D. (2014). Generalized linear mixed joint model for longitudinal and survival outcomes. *Statistics and Computing*, **24**, 417–427.
- Viviani, S., Rizopoulos, D. and Alfó, M. (2014). Local sensitivity of shared parameter models to nonignorability of dropout. *Statistical Modelling* **14**, 205–228.
- Wang, Y. and Taylor, J. (2001). Jointly modeling longitudinal and event time data with application to acquired immunodeficiency syndrome. *Journal of the American Statistical Association* **96**, 895–905.

2.10 Additional References (cont'd)

- Wu, M. and Bailey, K. (1988). Analysing changes in the presence of informative right censoring caused by death and withdrawal. *Statistics in Medicine* **7**, 337–346.
- Wu, M. and Bailey, K. (1989). Estimation and comparison of changes in the presence of informative right censoring: conditional linear model. *Biometrics* **45**, 939–955.
- Wu, M. and Carroll, R. (1988). Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process. *Biometrics* **44**, 175–188.
- Wulfsohn, M. and Tsiatis, A. (1997). A joint model for survival and longitudinal data measured with error. *Biometrics* **53**, 330–339.
- Xu, C., Baines, P. and Wang, J.-L. (2014). Standard error estimation using the EM algorithm for the joint modeling of survival and longitudinal data. *Biostatistics*, to appear.
- Xu, J. and Zeger, S. (2001). Joint analysis of longitudinal data comprising repeated measures and times to events. *Applied Statistics* **50**, 375–387.

2.10 Additional References (cont'd)

- Ye, W., Lin, X., and Taylor, J. (2008). Semiparametric modeling of longitudinal measurements and time-to-event data a two stage regression calibration approach. *Biometrics* **64**, 1238–1246.
- Yu, M., Law, N., Taylor, J., and Sandler, H. (2004). Joint longitudinal-survival-cure models and their application to prostate cancer. *Statistica Sinica* **14**, 835–862.
- Yu, M., Taylor, J. and Sandler, H. (2008). Individualized prediction in prostate cancer studies using a joint longitudinal-survival-cure model. *Journal of the American Statistical Association* **108**, 178–187.
- Zeng, D. and Cai, J. (2005). Asymptotic results for maximum likelihood estimators in joint analysis of repeated measurements and survival time. *The Annals of Statistics* **33**, 2132–2163.
- Zheng, Y. and Heagerty, P. (2007). Prospective accuracy for longitudinal markers. *Biometrics* **63**, 332–341.

2.11 Medical Papers with Joint Modeling

- Andrinopoulou, E.R., Rizopoulos, D., Jin, R., Bogers, A., Lesaffre, E. and Takkenberg, J. (2012). An introduction to mixed models and joint modeling: Analysis of valve function over time. *Annals of Thoracic Surgery* **93**, 1765–1772.
- Andrinopoulou, E.R., Rizopoulos, D., Geleijnse, M., Lesaffre, E., Bogers, A. and Takkenberg, J. (2015). Dynamic prediction of outcome for patients with severe aortic stenosis: Application of joint models for longitudinal and time-to-event data. *BMC Cardiovascular Disorders*, to appear.
- Daher Abdi, D.Z., Essig, M., Rizopoulos, D., Le Meur, Y., Premaud, A., Woillard, J.-B., Rerolle, J.-P., Marquet, P. and Rousseau, A. (2013). Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach. *Pharmacological Research* **72**, 52–60.
- Ibrahim, J., Chu, H. and Chen, L.-M. (2010). Basic concepts and methods for joint models of longitudinal and survival data. *Journal of Clinical Oncology* **28**, 2796–2801.
- Nunez, J., Nunez, E., Rizopoulos, D., Minana, G., Bodi, V., Bondanza, L., Husser, O., Merlos, P., Santas, E., Pascual-Figal, D., Chorro, F. and Sanchis, J. (2014). Red blood cell distribution width is longitudinally associated with mortality and incident anemia in heart failure patients. *Circulation Journal* **78**, 410–418.
- Rizopoulos, D. and Takkenberg, J. (2014). Tools & Techniques: Dealing with time-varying covariates in survival analysis - joint models versus Cox models. *EuroIntervention* **10**, 285–288.

2.11 Medical Papers with Joint Modeling (cont'd)

- Thabut, G., Christie, J., Mal, H., Fournier, M., Brugiere, O., Leseche, G., Castier, Y. and Rizopoulos, D. (2013). Survival benefit of lung transplant for cystic fibrosis since lung-allocation-score implementation. *American Journal of Respiratory and Critical Care Medicine* **187**, 1335–1340.
- van der Linde, D., Roos-Hesselink, J., Rizopoulos, D., Heuvelman, H., Budts, W., van Dijk, A., Witsenburg, M., Yap, S., Bogers, A., Oxenius, A., Silversides, C., Oechslin, E. and Takkenberg, J. (2013). Surgical outcome of discrete subaortic stenosis in adults: A multicenter study. *Circulation* **127**, 1184–1191.
- van der Linde, D., Takkenberg, J., Rizopoulos, D., Heuvelman, H., Budts, W., van Dijk, A., Witsenburg, M., Yap, S., Bogers, A., Oxenius, A., Silversides, C., Oechslin, E. and Roos-Hesselink, J. (2013). Natural history of discrete subaortic stenosis in adults: A multicenter study. *European Heart Journal* **34**, 1548–1556.